Pure Global
NCT05048615

Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML

Efficacy and Safety of Ambulatory Low-dose Venetoclax and Azacitidne as First Line Therapy in Newly Diagnosed AML: a Pilot Study
Hospital Universitario Dr. Jose E. Gonzalez·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
AML
Drug/Device/Intervention
Venetoclax 100 MG
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Location
Monterrey, Mexico
Timeline & enrollment
Phase
Phase 2
Start date
Jul 26, 2021
End date
Jul 01, 2022
Enrollment
15 participants
Primary outcome

Feasibility will be address by obtaining the proportion of patients who need hospitalization,Safety will be defined by the number of patients deceased before 14 days of initiating treatment

Summary

Venetoclax plus azacitidine are effective in treating newly diagnosed AML in patients who
 cannot recieve intensive chemotherapy. However there is no clinical data rewarding the
 efficacy and safety of low-dose venetoclax and azacitidine as first-line therapy.

ICD-10 classifications
Acute myeloblastic leukaemia [AML]
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05048615
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05048615 through Pure Global AI's free database. This Phase 2 trial is sponsored by Hospital Universitario Dr. Jose E. Gonzalez and is currently Recruiting. The study focuses on AML. Target enrollment is 15 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.